From: Inadequate reporting quality of registered genome editing trials: an observational study
Trial design features | No. (%) of trials |
---|---|
Study type: | |
Interventionala | 78 (96.3) |
Long-term follow-upb | 3 (3.7) |
Primary purpose:c | |
Treatmentd | 63 (80.8) |
Other | 2 (2.6) |
Not providede | 13 (16.7) |
Study phase:c | |
Phase 0 | 3 (3.8) |
Early phase 1 | 4 (5.1) |
Phase 1 | 37 (47.4) |
Phase 2 | 7 (9.0) |
Phase 1/2 | 20 (25.6) |
Stated “not applicable” | 6 (7.7) |
Not providedf | 1 (1.3) |
Allocation:c | |
Randomized controlled trialg | 6 (7.7) |
Non-randomized trial | 23 (29.5) |
Not precisely stated, but single arm reported | 7 (9.0) |
Stated “not applicable” | 38 (48.7) |
Not provided | 4 (5.1) |
Intervention study model:c | |
Single group | 47 (60.3) |
Parallel | 14 (17.9) |
Sequential | 15 (19.2) |
Not provided | 2 (2.6) |
Masking:c | |
Open-label | 61 (78.2) |
Single-blindh | 3 (3.8) |
Double-blindi | 1 (1.3) |
Stated “not applicable” | 5 (6.4) |
Not provided | 8 (10.3) |
Placebo:c | |
Placebo comparator notedj | 3 (3.8) |
Not provided | 75 (96.2) |